You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

DURICEF Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Duricef patents expire, and what generic alternatives are available?

Duricef is a drug marketed by Warner Chilcott and is included in three NDAs.

The generic ingredient in DURICEF is cefadroxil/cefadroxil hemihydrate. Twenty-two suppliers are listed for this compound. Additional details are available on the cefadroxil/cefadroxil hemihydrate profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DURICEF?
  • What are the global sales for DURICEF?
  • What is Average Wholesale Price for DURICEF?
Summary for DURICEF
Drug patent expirations by year for DURICEF
Recent Clinical Trials for DURICEF

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of IowaPhase 4
University of Colorado, DenverPhase 1
GlaxoSmithKlinePhase 4

See all DURICEF clinical trials

US Patents and Regulatory Information for DURICEF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Warner Chilcott DURICEF cefadroxil/cefadroxil hemihydrate CAPSULE;ORAL 050512-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Warner Chilcott DURICEF cefadroxil/cefadroxil hemihydrate FOR SUSPENSION;ORAL 050527-003 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Warner Chilcott DURICEF cefadroxil/cefadroxil hemihydrate CAPSULE;ORAL 050512-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Warner Chilcott DURICEF cefadroxil/cefadroxil hemihydrate FOR SUSPENSION;ORAL 050527-002 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Warner Chilcott DURICEF cefadroxil/cefadroxil hemihydrate TABLET;ORAL 050528-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.